Search Results - "Targato, G."

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group by Gampenrieder, S.P., Dezentjé, V., Lambertini, M., de Nonneville, A., Marhold, M., Le Du, F., Cortés Salgado, A., Alpuim Costa, D., Vaz Batista, M., Chic Ruché, N., Tinchon, C., Petzer, A., Blondeaux, E., Del Mastro, L., Targato, G., Bertucci, F., Gonçalves, A., Viret, F., Bartsch, R., Mannsbart, C., Deleuze, A., Robert, L., Saavedra Serrano, C., Gion Cortés, M., Sampaio-Alves, M., Vitorino, M., Pecen, L., Singer, C., Harbeck, N., Rinnerthaler, G., Greil, R., Balic, Marija, Heibl, Sonja, Zabernigg, August Felix, Egle, Daniel, Sandholzer, Margit, Roitner, Florian, Andel, Johannes, Pichler, Petra, Hager, Christopher, Knauer, Michael, Hubalek, Michael, Bighin, Claudia, De Laurentiis, Michelino, De Placido, Sabino, Puglisi, Fabio, Boni, Luca, de Gregorio, Amelie, Degenhardt, Tom, Formisano, Luigi, Beelen, Karin, Robinson, Timothy, Fitzpatrick, Amanda, Dieras, Veronique, Muller, Volkmar, Gennari, Alessandra, Linn, Sabine, Braga, Sofia, Cortes, Javier, Palmieri, Carlo

“…Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a…”
Get full text

1595P Incidence and characterization of end-of-life (EoL) systemic anticancer therapy (SACT) in melanoma patients (pts): A monocentric experience by Buriolla, S., Pravisano, F., Costa, J., Alberti, M., Bortolus, G., Zapelloni, G., De Pieri, G., Targato, G., Pascoletti, G., Puglisi, F., Fasola, G., Minisini, A.M.M.

Get full text

1626P The perks of SARS-CoV-2 monitoring through serial nasopharyngeal (NP) swabs in an Italian high prevalence area by Bortot, L., Cinausero, M., Iacono, D., Corvaja, C., Pelizzari, G., Targato, G., Zara, D., Andreotti, V.J., Noto, C., Donato, R., Bin, A., Minisini, A.M.M., Fasola, G.

Get full text

1312P Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy by Pelizzari, G., Corvaja, C., Targato, G., Buriolla, S., Bortolot, M., Torresan, S., Fantin, A., De Maglio, G., Rossetto, C., Rizzato, S., Fasola, G., Follador, A.

Get full text

249P A retrospective analysis on capecitabine and vinorelbine combination in metastatic breast cancer: The MARCELLINO study by de Scordilli, M., Bortot, L., Cucciniello, L., Totaro, F., Mazzeo, R., Alberti, M., Palmero, L., Targato, G., Dri, A., Pravisano, F., Zapelloni, G., Lisanti, C., Spazzapan, S., Minisini, A.M.M., Mansutti, M., Bonotto, M., Gerratana, L., Fasola, G., Puglisi, F.

Get full text

876P An observational retrospective study on microsatellite instability (MSI) in metastatic melanoma by Targato, G., Poletto, E., Buriolla, S., de Scordilli, M., Pravisano, F., Pascoletti, G., De Maglio, G., Battiston, M., Angione, V., Turina, M., Pizzolitto, S., Cesselli, D., Bulfoni, M., Scott, C.A., Marzinotto, S., Di Loreto, C., Puglisi, F., Fasola, G., Minisini, A.M.M.

Get full text

415P Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET) by Cucciniello, L., Noto, C., Bolzonello, S., Molteni, E., Da Ros, L., Pastò, B., Franzoni, A., Spazzapan, S., Russo, S., Foffano, L., Buriolla, S., Targato, G., Allegri, L., Dri, A., Della Rossa, S., Bonotto, M., Damante, G., Belletti, B., Gerratana, L., Puglisi, F.

Get full text

342P Different modalities of detection breast cancer recurrences: A 5-year retrospective cohort study by Zara, D., Palmero, L., Targato, G., Giavarra, M., Basile, D., Vitale, M.G., Bertoli, E., Mansutti, M., Bonotto, M., Puglisi, F., Fasola, G., Minisini, A.M.

Get full text

1741P Triage procedures for COVID-19 in an Italian cancer centre by Targato, G., Zara, D., Fioraso, R., Bortot, L., Pelizzari, G., Corvaja, C., Palmero, L., Puglisi, F., Andreetta, C., Cardellino, G.G., Minisini, A.M., Fasola, G.

Get full text

295P Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi) by Bortot, L., Basile, D., Targato, G., Zara, D., Palmero, L., Alberti, M., Buriolla, S., Noto, C., Pascoletti, G., Poletto, E., Andreetta, C., Russo, S., Mansutti, M., Gerratana, L., Bonotto, M., Fasola, G., Puglisi, F., Minisini, A.M.M.

Get full text

252P Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload? by Noto, C., Dri, A., Pravisano, F., Residori, M., Bortot, L., Buriolla, S., Targato, G., Andreetta, C., Pascoletti, G., Poletto, E., Russo, S., Mansutti, M., Minisini, A.M.M., Puglisi, F., Fasola, G., Bonotto, M.

Get full text

261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes by Cerbone, L., Blondeaux, E., Boni, L., Ruelle, T., Russo, S., Bonotto, M., Targato, G., De Laurentiis, M., Piezzo, M., Arpino, G., Pugliese, P., Fabi, A., D'Alonzo, A., Giannubilo, I., Conte, B., Mulinelli, C., Lambertini, M., Bighin, C., Del Mastro, L.

Get full text

293P Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) by Mazzeo, R., Bortot, L., Michelotti, A., Buriolla, S., Palmero, L., Franzoni, A., Bertoli, E., Targato, G., Allegri, L., Da Ros, L., Alberti, M., Di Nardo, P., Bonotto, M., Sodde, S., Belletti, B., Spazzapan, S., Baldassarre, G., Damante, G., Gerratana, L., Puglisi, F.

Get full text

1045P Comparison between first-line target therapy and immunotherapy in different prognostic categories of BRAF mutant metastatic melanoma patients by Marconcini, R., Fava, P., F. de Rosa, De Tursi, M., Tanda, E.T., Consoli, F., Targato, G., Pimpinelli, N., Morgese, F., Bersanelli, M., Tucci, M.G., Saponara, M., Cortellini, A., Ocelli, M., Morganti, R., Manacorda, S., Bazzurri, S., Nuzzo, A., Ferrari, M., Falcone, A.

Get full text

Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program? by Giavarra, M., Bertoli, E., Buoro, V., Zara, D., Targato, G., Palmero, L., Vitale, M.G., Pelizzari, G., Basile, D., Gerratana, L., Bonotto, M., Andreetta, C., Cinausero, M., Pascoletti, G., Poletto, E., Russo, S., Puglisi, F., Fasola, G., Mansutti, M., Minisini, A.M.

Get full text

1367PImpact of sarcopenia in patients with metastatic melanoma treated with immunotherapy by Vitale, M G, Basile, D, Bertoli, E, Giavarra, M, Pelizzari, G, Palmero, L, Zara, D, Targato, G, Pascoletti, G, Cinausero, M, Poletto, E, Iacono, D, Puglisi, F, Fasola, G, Minisini, A M

“…Abstract Background High BMI is associated with better survival in metastatic melanoma patients (MM pts), while sarcopenia is linked to poorer outcome in pts…”
Get full text

1367P - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy by Vitale, M.G., Basile, D., Bertoli, E., Giavarra, M., Pelizzari, G., Palmero, L., Zara, D., Targato, G., Pascoletti, G., Cinausero, M., Poletto, E., Iacono, D., Puglisi, F., Fasola, G., Minisini, A.M.

“…High BMI is associated with better survival in metastatic melanoma patients (MM pts), while sarcopenia is linked to poorer outcome in pts with stage III. The…”
Get full text

Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy by Vitale, M.G., Basile, D., Bertoli, E., Giavarra, M., Pelizzari, G., Palmero, L., Zara, D., Targato, G., Pascoletti, G., Cinausero, M., Poletto, E., Iacono, D., Puglisi, F., Fasola, G., Minisini, A.M.

Get full text

236P - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program? by Giavarra, M., Bertoli, E., Buoro, V., Zara, D., Targato, G., Palmero, L., Vitale, M.G., Pelizzari, G., Basile, D., Gerratana, L., Bonotto, M., Andreetta, C., Cinausero, M., Pascoletti, G., Poletto, E., Russo, S., Puglisi, F., Fasola, G., Mansutti, M., Minisini, A.M.

“…Cancer multidisciplinary team meetings (MDMs) are commonly acknowledged as a good clinical practice. One of the roles of MDMs is to identify the best…”
Get full text

236PClinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program? by Giavarra, M, Bertoli, E, Buoro, V, Zara, D, Targato, G, Palmero, L, Vitale, M G, Pelizzari, G, Basile, D, Gerratana, L, Bonotto, M, Andreetta, C, Cinausero, M, Pascoletti, G, Poletto, E, Russo, S, Puglisi, F, Fasola, G, Mansutti, M, Minisini, A M

“…Abstract Background Cancer multidisciplinary team meetings (MDMs) are commonly acknowledged as a good clinical practice. One of the roles of MDMs is to…”
Get full text